PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.09%
Cash & equivalents declining -24.09% while TRAW's grows 101.11%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-24.09%
Below half of TRAW's 101.11%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.04%
Below half of TRAW's 74.48%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-17.11%
1.25-1.5x TRAW's -12.00%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.78%
Similar yoy growth to TRAW's -11.32%. Walter Schloss finds parallel expansions in non-current assets.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Below half of TRAW's 73.36%. Michael Burry sees a potential red flag for stagnation or capital shortage.
86.42%
Above 1.5x TRAW's 45.34%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
-55.20%
Less than half of TRAW's 10.88%. David Dodd sees fewer expansions in other current obligations.
21.67%
Less than half of TRAW's -0.96%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.67%
Similar yoy to TRAW's 27.68%. Walter Schloss sees parallel expansions in total liabilities.
0.96%
Less than half of TRAW's 151.85%. David Dodd sees fewer share issuances vs. competitor.
-5.35%
≥ 1.5x TRAW's -0.48%. David Dodd sees higher yoy retained profits than competitor.
-15.38%
Less than half of TRAW's 10.53%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Below half TRAW's 654.72%. Michael Burry sees potential underperformance in building shareholder capital.
-19.98%
Below half TRAW's 73.36%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
23.76%
Less than half of TRAW's -101.11%. David Dodd sees better deleveraging or stronger cash buildup than competitor.